Journal
IMMUNITY
Volume 51, Issue 1, Pages 15-26Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2019.06.021
Keywords
-
Categories
Funding
- PCF-Young Investigator Award
- SCRC for ALPD & Cirrhosis - NIAAA [P50 AA011999]
- NIH [R01 AI043477, R01 CA211794]
- Tower Cancer Research Foundation
- Padres Pedal the Cause C3 award [PTC2018]
- [U01 AA027681]
- [P01 CA128814]
Ask authors/readers for more resources
In many settings, tumor-associated inflammation, supported mainly by innate immune cells, contributes to tumor growth. Initial innate activation triggers secretion of inflammatory, regenerative, and anti-inflammatory cytokines, which in turn shape the adaptive immune response to the tumor. Here, we review the current understanding of the intricate dialog between cancer-associated inflammation and anti-tumor immunity. We discuss the changing nature of these interactions during tumor progression and the impact of the tissue environment on the anti-tumor immune response. In this context, we outline important gaps in current understanding by considering basic research and findings in the clinic. The future of cancer immunotherapy and its utility depend on improved understanding of these interactions and the ability to manipulate them in a predictable and beneficial manner.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available